Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cerebroside sulfatase - Takeda

X
Drug Profile

Cerebroside sulfatase - Takeda

Alternative Names: Arylsulfatase A; HGT-1110; HGT-1111; Metazym; Recombinant human arylsulfatase A; Recombinant human cerebroside sulfatase; Recombinant human sulfatidate sulfatase; rhASA; SHP-611; Sulfatide sulfatase; TAK 611

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zymenex A/S
  • Developer Assistance Publique Hopitaux de Paris; Takeda; Zymenex A/S
  • Class Arylsulfatases; Recombinant proteins
  • Mechanism of Action Cerebroside sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metachromatic leukodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Metachromatic leukodystrophy

Most Recent Events

  • 25 Apr 2022 Cerebroside sulfatase is still in phase II trial for metachromatic leukodystrophy in USA, the UK, Japan, Italy, Greece, Argentina, the Netherlands, Belgium, Brazil, Canada, France, Germany, Israel, Mexico and Spain (EudraCT2018-003291-12; NCT03771898)
  • 02 Apr 2022 Pooled efficacy data from rhASA-01, rhASA-03 and rhASA-05 trials in Metachromatic leukodystrophy presented at the 74th Annual Meeting of the American Academy of Neurology 2022 (AAN-2022)
  • 01 Apr 2022 Phase-II clinical trials in Metachromatic leukodystrophy (In children) in Argentina (Intrathecal) (NCT03771898) (EudraCT2018-003291-12)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top